Japan greenlights durvalumab and tremelimumab in combination with chemotherapy; US approves companion diagnostic tool for certain TKIs and expands indications for pemetrexed injection. Read more
US Food and Drug Administration approves two combinations for non-small cell lung cancer. Read more
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
Pan-Chyr Yang, MD, PhD+more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
Matthew Z. Guo, BA+more
With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab. Read more
In Brief for May 25, 2022
Erin Jungmeyer5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring. Read more
Winship Cancer Institute announces preceptor opportunity. NICE recommends tepotinib for select patients. Read more
The FDA Explained: An Interview with Dr. Harpreet Singh
Lung Cancer ConsideredDuring an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights. Read more
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time. Read more
Taiwan OKs nivolumab IV infusion in some cases. UK approves atezolizumab for NSCLC. European Commission greenlights lorlatinib for advanced ALK-positive disease. Read more
Sotorasib earns approval in European Union, Japan. Scotland OKs osimertinib. Read more